PRCT
PROCEPT BioRobotics Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -15.8% ·
share flow -1.9% ·
net new positions -18.8%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 94 | +5 | 33.31M | $752.45M | +11 | −5 |
| Q1 2026 | 91 | -1 | 33.28M | $833.46M | +12 | −14 |
| Q4 2025 | 93 | +1 | 39.36M | $1.24B | +3 | −1 |
| Q3 2025 | 16 | -3 | 25.33M | $904.19M | — | −3 |
| Q2 2025 | 16 | 0 | 23.48M | $1.35B | +1 | −1 |
| Q1 2025 | 13 | +2 | 6.67M | $388.41M | +2 | — |
| Q4 2024 | 11 | 0 | 6.19M | $498.09M | +1 | −1 |
| Q3 2024 | 10 | -1 | 3.73M | $299.03M | — | −1 |
| Q2 2024 | 11 | — | 4.04M | $246.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 8.04M | +3.0% | $286.81M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | The Vanguard Group ✦ (passive) | 5.21M | -0.8% | $185.78M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (passive) | 4.22M | +0.3% | $150.63M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 4 | State Street Global Advisors ✦ (passive) | 1.32M | +4.4% | $47.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.31M | +0.6% | $46.66M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | JPMorgan Chase ✦ | 1.22M | — | $43.39M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 7 | T. Rowe Price ✦ | 875.18K | -33.8% | $31.24M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | Baillie Gifford ✦ | 858.83K | -2.0% | $30.65M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 9 | Morgan Stanley ✦ | 843.67K | — | $30.11M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 10 | Wellington Management ✦ | 437.15K | -28.9% | $15.60M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 11 | Marshall Wace ✦ | 381.53K | +9100.2% | $13.62M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 12 | Goldman Sachs Group ✦ | 275.87K | — | $9.85M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Two Sigma Investments ✦ | 144.18K | -58.6% | $5.15M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Millennium Management ✦ | 105.06K | -44.8% | $3.75M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 66.34K | +24.1% | $2.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 16 | Citadel Advisors ✦ | 36.75K | +360.2% | $1.31M | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $5.76M | was 0.0% |
| D. E. Shaw & Co. | $4.24M | was 0.0% |
| Point72 Asset Management | $3.70M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 254 holders, 55.53M shares, $1.28B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President, CEO · 23.90K sh @ 20.85 · $498,315
Open-market sales (S)
Officer · 373 sh · $7,815
Officer · 297 sh · $6,223
Officer · 373 sh · $7,815
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology